Phase II Trial of Sunitinib in BAC or Never-smokers with Any Lung Adenocarcinoma

Article

Sunitinib is a new oral drug for advanced stage lung cancer. This study will determine the efficacy of sunitinib in patients with bronchoalveolar carcinoma (BAC) and in never-smokers with any type of adenocarcinoma.

Study Type: Interventional

Age/Sex Requirements: 18 years+ (None)

Sponsor: Swedish Medical Center, Pfizer

ClinicalTrials.gov Identifier: NCT00430261

Purpose: Sunitinib is a new oral drug for advanced stage lung cancer. This study will determine the efficacy of sunitinib in patients with bronchoalveolar carcinoma (BAC) and in never-smokers with any type of adenocarcinoma. Treatment will consist of 50 mg of sunitinib by mouth once a day for 4 weeks on followed by 2 weeks off for a 6-week cycle. Primary outcome measures include progression-free survival and time to progression.

Click here to learn more about this clinical trial.

Related Videos
Katie Ross-Driscoll, PhD, MPH | Credit: Regenstrief Institute
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
Shauna Applin, ARNP, an expert on HIV
© 2024 MJH Life Sciences

All rights reserved.